Mayfield Pharmaceuticals to Present at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10, 2...
October 08 2019 - 7:35AM
Mayfield Pharmaceuticals, the women’s health-focused subsidiary of
Harrow Health, Inc. (NASDAQ: HROW), today announced its Chief
Executive Officer, Melissa Bradford-Klug, will discuss Mayfield’s
advancements in developing new anti-infective medications such as
its MAY-66 drug candidate for recurrent bacterial vaginosis, as
well as Mayfield’s programs for dyspareunia and interstitial
cystitis, at the SVB Leerink New Treatments Focused on Women’s
Health Conference on October 10th, 2019 at 3:45 p.m. ET at the SVB
Leerink offices in New York, NY. Bradford-Klug will be
available to meet with attendees who may contact their SVB Leerink
representative to arrange for a meeting.
Mayfield is focused on making a difference in
women’s lives by being a voice for women and, in turn, developing
branded pharmaceutical products that address their significant
unmet healthcare needs.
Mayfield’s drug candidate pipeline includes:
- MAY-66, which is a first-in-class new chemical entity drug
candidate intended to prevent recurrent bacterial vaginosis
(BV). MAY-66 has produced extraordinarily promising data in
what we believe is a translatable pre-clinical model.
Approximately 21 million women in the U.S. are estimated to suffer
from BV and high reoccurrence rates of BV are an ongoing
need. Complications of BV, if left untreated, include
increased risk of acquiring and transmitting HIV, increased risk of
preterm birth and reduction in fertility during IVF therapy.
The addressable market for MAY-66 is estimated at $1 billion
annually in the U.S.
- MAY-44, which is being developed for the temporary relief of
dyspareunia in breast cancer survivors and pre-menopausal and
post-menopausal women. MAY-44 is protected by three issued
patents and could become the first FDA-approved topical
non-estrogen-based product to address a market of as many as 34
million American women for whom dyspareunia is common. The
dyspareunia indication Mayfield will seek approval for is an
estimated $2.1 billion annual U.S. market opportunity.
- MAY-88, which is a patent-pending oral suspension that Mayfield
will develop for the treatment of moderate to severe interstitial
cystitis (IC). Mayfield believes the IC drug market,
currently estimated at $400 million annually, is highly underserved
and in need of new treatment options for an estimated 8 million
U.S. patients who chronically suffer from IC. Mayfield’s
MAY-88 is initially pursuing an orphan population within the IC
market.
About Mayfield
Pharmaceuticals
Mayfield Pharmaceuticals, Inc. is a
pharmaceutical company focused on the development of branded
solutions that address the unmet needs of women. Mayfield
intends to seek regulatory approval for its drug candidates through
the U.S. Food and Drug Administration’s 505(b)(1) and 505(b)(2)
regulatory pathways. Mayfield’s current drug candidates will
pursue indications for recurrent bacterial vaginosis, dyspareunia,
and interstitial cystitis, which are collectively estimated to
present an addressable market opportunity that exceeds $3 billion
annually in the U.S.
About Harrow Health
Harrow Health, Inc. (NASDAQ: HROW) owns a
portfolio of healthcare businesses, including ImprimisRx, the
nation’s leading ophthalmology outsourcing facility and
pharmaceutical compounding business. The company holds large
equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals,
Melt Pharmaceuticals, Mayfield Pharmaceuticals, Stowe
Pharmaceuticals and Radley Pharmaceuticals, all companies founded
as subsidiaries of Harrow Health. The Company also owns
royalty rights in certain drug candidates being developed by
Surface, Melt, Mayfield and Radley. Harrow intends to create,
invest in and grow paradigm shifting healthcare businesses that put
patients first. For more information about Harrow Health,
please visit the Investor Relations section of the corporate
website by clicking here.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Any statements in this release that
are not historical facts may be considered such "forward-looking
statements." Forward-looking statements are based on management's
current expectations and are subject to risks and uncertainties
which may cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include our ability to make commercially available our
compounded formulations and technologies in a timely manner or at
all; physician interest in prescribing our formulations; risks
related to our compounding pharmacy operations; our ability to
enter into other strategic alliances, including arrangements with
pharmacies, physicians and healthcare organizations for the
development and distribution of our formulations; our ability to
obtain intellectual property protection for our assets; our ability
to accurately estimate our expenses and cash burn, and raise
additional funds when necessary; risks related to research and
development activities; the projected size of the potential market
for our technologies and formulations; unexpected new data, safety
and technical issues; regulatory and market developments impacting
compounding pharmacies, outsourcing facilities and the
pharmaceutical industry; competition; and market conditions. These
and additional risks and uncertainties are more fully described in
Harrow Health’s filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Such documents may be read free of
charge on the SEC's web site at www.sec.gov. Undue reliance should
not be placed on forward-looking statements, which speak only as of
the date they are made. Except as required by law, Harrow Health
undertakes no obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
Investor Contact:Jon
Pattonjpatton@harrowinc.com858-704-4587
Source: Mayfield Pharmaceuticals, Inc. and Harrow Health,
Inc.
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Mar 2024 to Apr 2024
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Apr 2023 to Apr 2024